CFCarrie E. Flanagan

Carrie E. Flanagan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Carrie E. Flanagan has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Rhinitis of Pregnancy and Hormonally Induced Rhinitis

    by Zachary Alexander Warren, Carrie Flanagan, Sarah Wise


  • Open Access

    Assessment of a Nano-Docetaxel Combined Treatment for Head and Neck Cancer

    by Gee Young Lee, Mohamed Mubasher, Tamra S. McKenzie, Nicole C. Schmitt, Merry E. Sebelik, Carrie E. Flanagan, Badi El Osta, Maya B. Cothran, Hadiyah-Nicole Green

    Objective: The combination of docetaxel (DTX) with Laser-Activated NanoTherapy (LANT), as a treatment for head and neck cancer (HNC), may enhance the therapeutic efficacy of lower doses of DTX, thereby minimizing the effective dosage, side effects and treatment times. Material and methods: Three HNSCC cell lines, Detroit 562, FaDu, and CAL 27, were treated with four combinations of DTX + LANT to evaluate DTX dose reduction and cell viability. Results: The 1 nM DTX + 5 nM LANT combination was the most effective treatment, increasing cell death over its corresponding DTX monotreatment with approximately 86.6%, 80.7%, and 92.1% cell death for Detroit 562, FaDu, and CAL 27, respectively. In Detroit 562, the 1 nM DTX + 5 nM LANT combination treatment resulted in the highest percentage of DTX dose reduction at 84.6%; in FaDu and CAL 27, the 0.5 nM DTX + 5 nM LANT combination treatment resulted in the highest percentage of DTX dose reduction at 78.2% and 82.4%, respectively. Conclusion: LANT may increase the therapeutic efficacy of DTX at significantly lower doses, which could improve patient outcomes.